Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.64 EUR | -1.50% | -4.84% | -3.97% |
Apr. 24 | CAC40: interest rates soar, pulling back below 8100 pts | CF |
Apr. 24 | EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The firm trades with high earnings multiples: 27.57 times its 2024 earnings per share.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.97% | 11.66B | A- | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+10.92% | 29.4B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-1.42% | 11.72B | A- | ||
-31.75% | 11.77B | - | - | |
+27.44% | 11.71B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERF Stock
- Ratings Eurofins Scientific SE